Study DesignGo to
interesting timing of patent approval with study completion date iminent
Study Type: Interventional (Clinical Trial) 1 ActualEnrollment: 88 participants 2 Allocation: Randomized 3 Intervention Model: Parallel Assignment 4 Masking: None (Open Label) 5 Primary Purpose: Treatment 6 Official Title: A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer 7 ActualStudy Start Date: July 2, 2018 8 ActualPrimary Completion Date: February 27, 2020 9 EstimatedStudy Completion Date: August 31, 2021
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-12
- There are more pages in this discussion • 732 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
45.5¢ |
Change
0.020(4.60%) |
Mkt cap ! $540.9M |
Open | High | Low | Value | Volume |
44.0¢ | 45.5¢ | 43.0¢ | $439.6K | 992.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.5¢ | 65958 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.450 |
3 | 180864 | 0.445 |
3 | 43917 | 0.440 |
1 | 12188 | 0.435 |
9 | 84739 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.455 | 65958 | 3 |
0.460 | 137714 | 6 |
0.465 | 122500 | 3 |
0.470 | 174033 | 5 |
0.475 | 69000 | 2 |
Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
Last
44.8¢ |
  |
Change
0.020 ( 3.21 %) |
|||
Open | High | Low | Volume | ||
44.0¢ | 45.0¢ | 43.0¢ | 240557 | ||
Last updated 15.59pm 17/05/2024 ? |
Featured News
IMM (ASX) Chart |